This article studies growth of China's listed biopharmaceutical companies. According to the Shenyin Wanguo industry classification criteria, 36 biopharmaceutical listed companies were selected, and 12 financial indicators were used to establish a growth index evaluation system. The factor analysis method was used to calculate the comprehensive growth scores of listed companies. The results show that the companies with comprehensive scores above 0.5 account for about 16.7%. The overall calculation result shows that the development space of the biopharmaceutical industry is relatively large, and the growth of China's biopharmaceutical listed companies still remain to improve. Combined with the results of factor analysis, we make recommendations, such as precise strategic planning and main business strengthening; improving talent introduction, increasing R&D investment; complying beneficial policies, and seizing development opportunities.